Objective:
To evaluate the effect of sugammadex on postoperative pulmonary complications in older adults undergoing major abdominal or thoracic surgery.
Approach:
- Study Design: An international, multicenter phase 4 clinical trial (SNaPP trial) involving 3,498 patients aged 40 years or older.
- Intervention: Patients were randomly assigned to receive either sugammadex or neostigmine at the end of surgery.
- Primary Endpoint: Postoperative pulmonary complications or mortality through hospital discharge or postoperative day 7.
- Secondary Outcomes: Included pulmonary complications, postoperative nausea and vomiting, unplanned intensive care admission, days alive and at home at 30 days, and health-related quality of life at 3 months.
Key Findings:
- Postoperative pulmonary complications or mortality occurred in about 19% of patients receiving sugammadex compared to 22% receiving neostigmine, with the reduction primarily due to fewer cases of atelectasis (18% vs 21%).
- Rates of pneumonia, pulmonary aspiration, and mortality were similar between the two groups.
- Sugammadex resulted in more complete reversal of neuromuscular blockade prior to tracheal extubation.
Interpretation:
The reduction in postoperative pulmonary complications was modest and mainly driven by atelectasis.
Limitations:
- Findings may not be generalizable beyond older adults undergoing major abdominal or thoracic surgery.
- Treating anesthesiologists could not be masked to treatment assignment, potentially influencing management decisions.
Conclusion:
Sugammadex may provide a modest reduction in postoperative pulmonary complications compared to neostigmine in older adults undergoing major surgery.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
